Primary CNS Lymphoma

HCT-ASCT consolidation in primary CNS lymphoma: 3-year progression-free survival 78% versus 51% in the phase 3 MATRix/IELSG43 trial

A research highlight in Nature Reviews Clinical Oncology endorses high-dose chemotherapy with autologous stem-cell transplantation (HCT-ASCT) as consolidation after induction in eligible patients with primary central nervous system lymphoma. The underlying evidence is the randomised phase 3 MATRix/I…